Harbin Medisan Pharmaceutical Co Ltd (002900) — Capital Reinvestment Ratio
Harbin Medisan Pharmaceutical Co Ltd (002900) has a Capital Reinvestment Ratio of 0.79x as of March 2025, meaning it reinvests 1% of its operating cash flow (CN¥86.31 Million) in capital expenditures (CN¥68.40 Million). Check 002900 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Harbin Medisan Pharmaceutical Co Ltd Capital Reinvestment Ratio (2012–2024)
This chart tracks Harbin Medisan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Harbin Medisan Pharmaceutical Co Ltd (002900) cash conversion ratio.
Annual Capital Reinvestment Ratio for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
Year-by-year Capital Reinvestment Ratio for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. See Harbin Medisan Pharmaceutical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 11.28x | CN¥30.69 Million | CN¥346.21 Million | ▲ +34.4% |
| 2023 | 8.39x | CN¥35.69 Million | CN¥299.58 Million | ▲ +1260.6% |
| 2022 | 0.62x | CN¥144.64 Million | CN¥89.22 Million | ▼ -0.6% |
| 2019 | 0.62x | CN¥320.14 Million | CN¥198.63 Million | ▲ +131.4% |
| 2018 | 0.27x | CN¥292.46 Million | CN¥78.41 Million | ▼ -42.9% |
| 2017 | 0.47x | CN¥223.46 Million | CN¥104.93 Million | ▲ +15.6% |
| 2016 | 0.41x | CN¥231.18 Million | CN¥93.88 Million | ▼ -42.4% |
| 2015 | 0.71x | CN¥200.85 Million | CN¥141.72 Million | ▼ -43.7% |
| 2014 | 1.25x | CN¥116.31 Million | CN¥145.81 Million | ▲ +35.9% |
| 2013 | 0.92x | CN¥167.10 Million | CN¥154.13 Million | ▲ +24.9% |
| 2012 | 0.74x | CN¥123.22 Million | CN¥91.01 Million | — |